C12N 2760/18734
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/18734 (Use of virus or viral component as vaccine) appears on 73 US grants and 77 published applications in this corpus.
Search patents in C12N- Granted patents
- 73
- Published applications
- 77
- Assignees
- 66
- Inventors
- 212
- Latest grant
- 9 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 0 | 0 |
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 3 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 4 | 0 |
| 2001 | 3 | 1 |
| 2002 | 0 | 1 |
| 2003 | 1 | 5 |
| 2004 | 1 | 3 |
| 2005 | 2 | 0 |
| 2006 | 1 | 0 |
| 2007 | 0 | 2 |
| 2008 | 2 | 2 |
| 2009 | 1 | 2 |
| 2010 | 1 | 2 |
| 2011 | 2 | 2 |
| 2012 | 0 | 2 |
| 2013 | 1 | 2 |
| 2014 | 4 | 5 |
| 2015 | 0 | 4 |
| 2016 | 1 | 2 |
| 2017 | 3 | 6 |
| 2018 | 4 | 5 |
| 2019 | 5 | 4 |
| 2020 | 2 | 3 |
| 2021 | 3 | 0 |
| 2022 | 3 | 9 |
| 2023 | 2 | 4 |
| 2024 | 3 | 4 |
| 2025 | 4 | 5 |
| 2026 | 4 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Oral respiratory vaccine9 Jun 2026US 12,648,991 B2Intervet Inc.
- Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/PIV3 F protein and uses thereof2 Jun 2026US 12,643,925 B2The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Paramyxovirus virus-like particles as protein delivery vehicles14 Apr 2026US 12,600,956 B2The Penn State Research Foundation
- Transient expression of biologic materials17 Mar 2026US 12,576,041 B1
- F-genotype mumps virus attenuated strain and construction method therefor and application thereof2 Dec 2025US 12,486,497 B2Beijing Cell-Fusion Biotechnology Co., Ltd.
- Piv5-based covid-19 vaccine12 Mar 2026US 2026/0069674 A9University of Georgia Research Foundation, Inc.
- Prefusion piv f immunogens and their use22 Jan 2026US 2026/0022145 A1Institute for Research in Biomedicine
- Piv5-based covid-19 vaccine16 Oct 2025US 2025/0319176 A1University of Georgia Research Foundation, Inc.
- Paramyxovirus virus-like particles as protein delivery vehicles10 Jul 2025US 2025/0223572 A1The Penn State Research Foundation
- Attenuated bordetella bronchiseptica strains, oral vaccines containing the attenuated strains, and methods of making & use thereof3 Jul 2025US 2025/0213669 A1Boehringer Ingelheim Animal Health USA Inc.
Most cited
By later US patents
- Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell40US 6,825,036 B2Juridical Foundation The Chemo-Sero-Therapeutic Research Institute · 2004
- Production of viruses in tissue culture without use of serum39US 4,072,565 AThe Dow Chemical Company · 1978
- Porcine parainfluenza virus type 233US 5,910,310 ABayer Aktiengesellschaft · 1999
- Multivalent canine distemper virus vaccine26US 5,000,951 ADiamond Scientific Co. · 1991
- Stabilizers for live vaccines25US 6,231,860 B1Pasteur Merieux Serums & Vaccins · 2001